Clinical Experience with Antiangiogenic Therapy in Leukemia
Journal:
Current Cancer Drug Targets
Volume:
11
Page:
1053-1068
Author(s):
J. Wellbrock and W. Fiedler
Hypoxia-Inducible Factors and Sphingosine 1-Phosphate Signaling
Journal:
Anti-Cancer Agents in Medicinal Chemistry
Volume:
11
Page:
854-862
Author(s):
Olivier Cuvillier and Isabelle Ader
Sphingolipid Metabolism and Leukemia: A Potential for Novel Therapeutic Approaches
Journal:
Anti-Cancer Agents in Medicinal Chemistry
Volume:
11
Page:
863-881
Author(s):
Tara Ann Burns and Chiara Luberto
Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Journal:
Anti-Cancer Agents in Medicinal Chemistry
Volume:
11
Page:
891-903
Author(s):
Valerie Gouaze-Andersson and Myles C. Cabot
Antiangiogenesis in Myelodysplastic Syndrome
Journal:
Current Cancer Drug Targets
Volume:
11
Page:
1044-1052
Author(s):
A. Aguayo, F. M. Armillas-Canseco and D. Martinez-Banos
Mechanisms Involved in Apoptosis Events Contributing to Sepsis-Induced Myocardial Dysfunction
Journal:
Current Drug Therapy
Volume:
6
Page:
286-295
Author(s):
Mani Chopra and Avadhesh C. Sharma
Recent Advances in the Design and Synthesis of Prednisolone and Methylprednisolone Conjugates
Journal:
Current Pharmaceutical Design
Volume:
17
Page:
3577-3595
Author(s):
Eliska Bilkova, Ales Imramovsky and Milos Sedlak
Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Journal:
Current Pharmaceutical Design
Volume:
17
Page:
3560-3576
Author(s):
Barbara Pavan and Alessandro Dalpiaz
Ceramidases in Hematological Malignancies: Senseless or Neglected Target?
Journal:
Anti-Cancer Agents in Medicinal Chemistry
Volume:
11
Page:
830-843
Author(s):
Gemma Fabrias, Carmen Bedia, Josefina Casas, Jose Luis Abad and Antonio Delgado
EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Journal:
Current Cancer Drug Targets
Volume:
11
Page:
1082-1097
Author(s):
RONG Biao-xue, CAI Xi-guang, YANG Shuan-ying, LI Wei and MING Zong-juan